Cell Transplantation: A Novel Therapeutic Modality for Cerebral Palsy with Co-Morbid Intellectual Disability

Sharma, Alok; Sane, Hemangi; Gokulch, ini; Kulkarni, Pooja; Jose, Alitta; Ganar, Vishal; Nivins, Samson; Badhe, Prerna

doi:10.21767/2471-8548.10010

Cited by 4 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UCBs and peripheral blood mononuclear cell infusion therapy for patients with CP improved brain glucose metabolism, as observed in PET studies 73 , 80 . Autologous BM-MNC therapies for patients with ASD also showed improvements in glucose metabolism and various cognitive and behavioral symptoms such as eye contact, attention and concentration, hyperactivity, sitting tolerance, social interaction, stereotypical behavior, aggressiveness, communication, speech, command following, and self-stimulatory behavior, as well as improvement of glucose metabolism and motor function in patients with CP 47 , 81 . In 2020, we reported that angiogenesis is activated by BM-MNCs via gap junction–mediated cell–cell interaction soon after cell transplantation and that cell–cell interaction via gap junctions is the prominent pathway for the activation of angiogenesis in endothelial cells and improvement of glucose uptake 82 .…”

Section: Discussionmentioning

confidence: 91%

“…Dawson et al reported safe and feasible autologous UCBs infusion in young children with ASD, and several promising outcomes have been published 39 – 42 . Recently, UC-MSCs (umbilical cord–derived MSC) and bone marrow mononuclear cells (BM-MNCs) from individuals with ASD had favorable outcomes 43 – 49 ( Table 2 ). Fetal stem cells for individuals with ASD have shown favorable outcomes, albeit instigating an ethical dilemma regarding the use of fetal stem cells.…”

Section: Pathophysiologymentioning

confidence: 99%

See 1 more Smart Citation

Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review

2023

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by difficulties in social communication, repetitive behaviors, and restricted interests, with onset early in life. The prevalence of ASD has increased worldwide in the last two decades. However, there is currently no effective therapy for ASD. Therefore, it is important to develop new strategies for ASD treatment. Evidence for the relationship between ASD and neuroinflammation, ASD and microglia, and ASD and glucose metabolism has increased rapidly in recent decades. We reviewed 10 clinical studies on cell therapies for individuals with ASD. Almost all studies showed good outcomes and no remarkable adverse events. Over the past decades, the neurophysiological characteristics of ASD have been shown to be impaired communication, cognition, perception, motor skills, executive function, theory of mind, and control of emotions. Recent studies have focused on the roles of immune pathology, such as neuroinflammation, microglia, cytokines, and oxidative stress, in ASD. We also focused on glucose metabolism in patients with ASD. The significance of gap junction–mediated cell–cell interactions between the cerebral endothelium and transplanted cells was observed in both bone marrow mononuclear cells and mesenchymal stromal cells transplantation. Owing to the insufficient number of samples, cell therapies, such as umbilical cord blood cells, bone marrow mononuclear cells, and mesenchymal stromal cells, will be a major challenge for ASD. As a result of these findings, a new paradigm for cell therapy for autism may emerge.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Pathophysiologymentioning

confidence: 99%

Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review

2023

View full text Add to dashboard Cite

show abstract

“…O Transtorno do Espectro Autista (TEA) faz parte de um grupo de transtornos que comprometem a interação social e a comunicação, e afetam o comportamento do indivíduo através da presença de interesses e atividades restritas e repetitivas (Fogo, 2018;Sampaio, 2019;Sharma et al, 2020). De acordo com Queiroz e Mendes (2017) e Pavin et al (2019), o psiquiatra austríaco Leo Kanner, descreveu, pela primeira vez, o TEA em 1943.…”

Section: Introductionunclassified

“…Os sintomas mais comuns do autismo incluem baixo contato visual, dificuldade no entendimento de sinais não verbais, déficit na oratória e cognição, comportamentos repetitivos e dependência nas atividades diárias (Sharma et al, 2020). O transtorno é diagnosticado através de uma análise clínica-comportamental, seguindo critérios delimitados pelo Manual de Diagnóstico e Estatístico de Transtornos Mentais (DSM) ou pela Classificação Internacional de Doenças (CID) (Evangelho et al, 2021).…”

Section: Introductionunclassified

See 1 more Smart Citation

Uso das células tronco na terapêutica de indivíduos com Transtorno de Espectro Autista - Revisão integrativa

Padilha,

Gonçalves,

Laranjeira

et al. 2024

RSD

View full text Add to dashboard Cite

O Transtorno do Espectro Autista (TEA) está associado a causas multifatoriais - genéticas e ambientais, como prematuridade, asfixia e exposição fetal ao álcool e drogas. Estudos indicam genes como NLGN4 e ASTN2 associados ao autismo. Os tratamentos se dividem em abordagens comportamentais, nutricionais e medicinais, porém, novos achados em epigenética e neuroimunologia sugerem que as terapias com células-tronco hematopoéticas podem ser potenciais intervenções para o tratamento de síndromes autistas. O objetivo deste trabalho foi realizar uma revisão integrativa sobre tema de Uso de Células Tronco na Terapêutica de Indivíduos com transtornos de Espectro Autista. Foram utilizadas as bases de dados PubMed, Scielo, Google Acadêmico e Adolec com artigos publicados entre os anos de 2010 e 2021. Para definir a pergunta de pesquisa foi utilizada a estratégia PICo (População, Fenômeno, Contexto). As Células-tronco são células precursoras não especializadas, que possuem habilidade de autorrenovação, capacidade de se diferenciar e a habilidade de reconstituição. No entanto, a problemática se apresenta na maneira de como um novo tratamento utilizando essa terapia pode influenciar na melhora do indivíduo com TEA, isso é identificado através da observação da influência do transplante dessas células em humanos, nas suas habilidades motoras e cognitivas. A etiologia do autismo nos estudos está indicada no envolvimento de desregulações imunológicas, mas a sua fisiopatologia permanece ainda mal definida e os mecanismos exatos do transplante ainda não foram confirmados e esclarecidos, o que sugere a continuação dos estudos a fim de verificar a eficácia dessa abordagem terapêutica a longo prazo.

show abstract

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Sharma¹,

Gokulchandran²,

Sane³

et al. 2023

Preprint

View full text Add to dashboard Cite

Bone marrow mononuclear cells (BMMNCs) have emerged as a potential therapeutic strategy for various incurable conditions including autism spectrum disorder (ASD). To study its safety and efficacy, we analyzed 1011 patients who underwent intrathecal administration of autologous BMMNCs along with neurorehabilitation. At mean follow-up of 19.3 months after intervention, 90.6% patients showed overall improvement. Improvements were observed in attention concentration, command following, eye contact, sitting tolerance, social interaction, hyperactivity, communication, speech, aggressiveness, stereotypical and self-injurious behavior. Statistically significant changes were observed in scores of Indian Scale of Autism Assessment and Childhood Autism Rating Scale (p<0.05). On subgroup analysis, improvements were recorded irrespective of age and disease severity and better outcome was observed in patients who took multiple doses of cell therapy compared to single dose. Comparative Brain PET-CT scan of 401 patients showed improved brain metabolism after the intervention. No major adverse events were reported. Only 9 out of 1011 patients experienced seizures which were managed using medications. 4 out of 9 had history of seizures while 5 had normal EEG with no history. However, improvements were still observed in these 9 patients. Thus, intrathecal transplantation of autologous BMMNCs along with neurorehabilitation is safe and efficacious in patients with ASD.

show abstract

Cell Transplantation: A Novel Therapeutic Modality for Cerebral Palsy with Co-Morbid Intellectual Disability

Cited by 4 publications

References 32 publications

Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review

Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review

Uso das células tronco na terapêutica de indivíduos com Transtorno de Espectro Autista - Revisão integrativa

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Contact Info

Product

Resources

About